Mark A. De Rosch
Mark A. De Rosch, PhD, FRAPS,
Dr. De Rosch is currently the Chief Regulatory Officer at Epizyme, Inc., a Cambridge-based biotech company focused on epigenetic therapies for oncology. Prior to Epizyme, he held executive-level Regulatory and Quality positions at Nightstar Therapeutics, Akebia Therapeutics, Voisin Consulting, and Inspiration Biopharmaceuticals. While at Vertex Pharmaceuticals, Dr. De Rosch led the regulatory strategy and approval process for Kalydeco, the first CFTR modulator approved for the treatment of cystic fibrosis. Mark received his BS from the University of Wisconsin-Parkside and his MS & PhD from the University of California, San Diego.